Amgen's (AMGN) Buy Rating Reaffirmed at Goldman Sachs Group Inc.


's stock had its "buy" rating reiterated by analysts at Goldman Sachs Group Inc. in a research note issued to investors on Tuesday. They presently have a $206.00 price target on the medical research company's stock, up from their prior price target of $204.00.



from Biotech News